Bloom logo

Bloom Health Partners Reports Profitable Fiscal Year 2021 with $9.8 Million in Revenue

Results show a strong first fiscal year, with $5.5 million in cash and continued growth from operations

Bloom Health Partners Inc. (CSE: BLMH) (OTCQB: BLMHF) (FSE: D840) ("Bloom" or the "Company"), a global platform for operational health, is pleased to announce performance for the Company's 2021 fiscal year ended September 30th, 2021.

Business Highlights in Fiscal 2021:

  • Completed reverse takeover with resulting listing on the Canadian Securities Exchange
  • Closed a private placement of $1,278,600 in May 2021
  • Completed acquisition of Round Hill Health Partners LLC in July 2021
  • Successfully integrated acquired operations and consolidated results in fiscal Q4, 2021
  • Completed 2021 fiscal year on September 30th, reporting revenue of $9,843,767 and Adjusted EBITDA(1) of $2,399,626

Fiscal 2021 Summary:

Financial information is reported in Canadian dollars and in accordance with International Financial Reporting Standards (IFRS), unless otherwise stated. The Company achieved revenues from the acquisition date of July 14, 2021 to September 30, 2021 of $9,843,767 and Adjusted EBITDA(1) of $2,399,626. Bloom's cash on hand at the end of Fiscal 2021 is $5,598,296.

In the first half of 2021, prior to the acquisition date, Round Hill Health Partners LLC, achieved $11,888,654 USD in revenues with $5,507,998 USD of net income in the first six calendar months of 2021, as reported in the Business Acquisition Report filed in connection with the acquisition and available under the profile for Bloom on SEDAR (www.sedar.com).

"We're thrilled with the results of our first full fiscal year," said Andrew Morton, CEO of Bloom. "As an Operational Health provider, we've set the stage to deliver successful Occupational Health Programs on our digital platform. Our business with film/TV productions, Fortune 500 companies and state school systems is providing a path to further expanding services and client base in 2022 and beyond. We're already showing growth since completion of fiscal 2021, with two recently announced state school contracts in Texas and Alabama, which are part of a US Government US$10 billion school testing program. We continue to advance discussions with other large organizations and look forward to updating the market as this progresses. Bloom has a strong management team and proven operations that are the foundation for growth by providing innovation in health and health-tech for large organizations."

Financial Statements and Management's Discussion and Analysis

For further details and analysis of our results, please refer to our annual audited financial statements and management's discussion and analysis for the year ended September 30, 2021, available on SEDAR at www.sedar.com.

Non-IFRS Financial Measures

We believe that providing certain non-IFRS financial measures provide users with important information regarding the operational performance of our business. The non-IFRS financial measures used by management do not have any standardized meaning prescribed by IFRS and therefore may not be comparable to similar measures presented by other issuers. Accordingly, these measures should not be considered as a substitute or alternative for IFRS measures as determined in accordance with IFRS. By considering these measures in combination with the comparable IFRS financial measures, we believe that users are provided a better overall understanding of our business and financial performance during the relevant period than if they considered the IFRS financial measures alone.

EBITDA and Adjusted EBITDA

EBITDA is defined as earnings before interest, income taxes, depreciation, and amortization and is utilized by management to assess and evaluate the financial performance of its operations. Management believes that EBITDA improves comparability between periods by eliminating the impact of interest, income taxes, depreciation, and amortization.

Adjusted EBITDA excludes items that are not considered to be indicative of operational and financial trends either by nature or amount to provide a better overall understanding of the Company's underlying business performance. The most directly comparable GAAP measure to EBITDA and Adjusted EBITDA is net income before tax, calculated as follows:



For the year ended September 30  

  2021     2020  
Net income before tax $ 149,452
$ (416,109 )
Amortization of intangibles
679,493

-
Depreciation
32,397

-
Interest expense
249,181

2,159  
EBITDA
1,110,523

(413,950 )
Listing expense
1,328,871

-
Gain on debt settlement
(39,768 )
-  
Adjusted EBITDA $ 2,399,626
$ (413,950 )

 

About Bloom Health Partners Inc.

Bloom Health Partners Inc. (CSE: BLMH) (OTCQB: BLMHF) (FSE: D840) is a global platform for healthcare security, diagnostic testing and occupational health-tech. Our mission is to ensure that "unstoppable is possible" for businesses and their employees through innovative, customized healthcare models. Bloom offers a system for businesses and organizations that helps engage employees and creates strategies to manage health and safety. Our stable, scalable system is an integrated health-tech platform that securely manages data while delivering comprehensive workplace health and safety outcomes.

For more information: investors@bloomhealthpartners.com

On behalf of the board of directors,

Bloom Health Partners Inc.

Andrew Morton, Chief Executive Officer

Forward-Looking Statements

This news release includes forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in the Company's forward-looking statements include the potential that milestones may not be satisfied, acquisitions may not achieve expected benefits, financing requirements, and the other risk factors described in the Company's filings with Canadian securities regulators on www.sedar.com. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.


(1) This is a non-IFRS measure. Refer to the section "Non-IFRS Financial Measures" for information on the calculation of these non-IFRS measures.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/112117

News Provided by Newsfile via QuoteMedia

BLMH:CNX
The Conversation (0)
Bloom Health Partners

Bloom Health Partners

Delivering Innovative Health-Tech Solutions for Today’s Workforce

Delivering Innovative Health-Tech Solutions for Today’s Workforce Keep Reading...
Seegnal (TSXV:SEGN)

Seegnal Presents Real-World Evidence on Reducing Fall Risk in Geriatric Patients at Caltcm Summit

Seegnal Inc. (TSXV: SEGN) ("Seegnal" or the "Corporation"), a global leader in AI-enhanced prescription intelligence, today announced real-world clinical results demonstrating how medication governance may reduce fall-risk drivers in older adults -- a significant clinical and financial challenge... Keep Reading...
Scientists working in a modern medical research laboratory.

Pathways to Commercialising Biotech Innovations

In the medical technology industry, innovation is only the first step. While key to long-term success, innovation is only as good as a company’s commercialisation strategy. Once a technology has been developed and proven, the organisation must then embark on a process to commercialise it for... Keep Reading...
HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Limited (ASX: HMD), a medical data and technology company leading the digital transformation of maternity care, is delighted to announce it has entered into a collaboration agreement with Garmin (NYSE: GRMN), a leading global provider of smartwatches and GPS-enabled products, aimed at... Keep Reading...
Cyclomedica

Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

Cyclopharm Limited (ASX: CYC) is pleased to announce the signing of a major contract with Hospital Corporation of America Healthcare (HCA), one of the largest single healthcare providers in the United States. This agreement marks a significant milestone for the company which will allow the... Keep Reading...
CONNEQT App Launches in USA as Pulse Deliveries Commence

CONNEQT App Launches in USA as Pulse Deliveries Commence

Cardiex Limited (CDX:AU) has announced CONNEQT App Launches in USA as Pulse Deliveries CommenceDownload the PDF here. Keep Reading...
Female doctor with clipboard talking to smiling female patient at hospital.

Revolutionizing Women's Health: Antifungal Innovation Brings New Investment Opportunities

The intersection of women's health and antifungal innovation represents a pivotal moment in healthcare, offering both transformative medical advancements and compelling investment opportunities. The groundbreaking developments in antifungal treatments specifically targeting women's health issues... Keep Reading...

Interactive Chart

Latest Press Releases

Related News